Binding of the monoclonal antibody RP215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis

Histopathology

Volumn 67, Issue 5, 2015, Pages 645-653

  Liu, Yang ^a,b   Liu, Dan ^c   Wang, Chong ^a,b   Liao, Qinyuan ^a,b   Huang, Jing ^a,b   Jiang, Dongyang ^a,b   Shao, Wenwei ^a,b   Yin, Cheng Cameron ^d   Zhang, Youhui ^e   Lee, Gregory ^f   Qiu, Xiaoyan ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CANCER HOSPITAL   (China)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Immunoglobulin G; Lung neoplasms; Prognosis

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RP215; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR MARKER;

A549 CELL LINE; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL SELECTION; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR VOLUME; ADENOCARCINOMA; BIOSYNTHESIS; GENETIC TRANSFECTION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; WESTERN BLOTTING;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; BLOTTING, WESTERN; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84943350046     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12686     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63; 11-30.
2. Chen G, Yi XH. Pathology and genetics of disease and tumours of the lung, pleura in China. Zhonghua Bing Li Xue Za Zhi 2005; 34; 490-493.
3. Travis W, Brambilla E, Muller-Hermelink H et al. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
4. Curado M, Edwards B, Shin H et al. Cancer incidence in five continents. Lyon: IARC Scientific Publications, 2007.
5. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012; 62; 220-241.
6. Nakamura N, Miyagi E, Murata S, Kawaoi A, Katoh R. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod. Pathol. 2002; 15; 1058-1067.
7. Hirano T, Gong Y, Yoshida K et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41; 155-162.
8. Suzuki A, Shijubo N, Yamada G et al. Napsin a is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol. Res. Pract. 2005; 201; 579-586.
9. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and P63 immunostaining in classification of lung carcinomas. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 415-420.
10. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum. Pathol. 2010; 41; 20-25.
11. Montezuma D, Azevedo R, Lopes P, Vieira R, Cunha AL, Henrique R. A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and P63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens. Virchows Arch. 2013; 463; 749-754.
12. Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001; 93; 330-336.
13. Yatabe Y, Mitsudomi T, Takahashi T. Ttf-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol. 2002; 26; 767-773.
14. Qiu X, Zhu X, Zhang L et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res. 2003; 63; 6488-6495.
15. Babbage G, Ottensmeier CH, Blaydes J, Stevenson FK, Sahota SS. Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Res. 2006; 66; 3996-4000.
16. Chen Z, Gu J. Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB J. 2007; 21; 2931-2938.
17. Zheng H, Li M, Ren W et al. Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Mol. Immunol. 2007; 44; 2221-2227.
18. Huang J, Sun X, Mao Y et al. Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse brain neurons. Int. J. Biochem. Cell Biol. 2008; 40; 1604-1615.
19. Huang J, Zhang L, Ma T, Zhang P, Qiu X. Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse testis and epididymis. J. Histochem. Cytochem. 2009; 57; 339-349.
20. Zheng J, Huang J, Mao Y et al. Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. J. Biol. Chem. 2009; 284; 13610-13619.
21. Zhang S, Mao Y, Huang J et al. Immunoglobulin gene locus events in epithelial cells of lactating mouse mammary glands. Cell. Mol. Life Sci. 2010; 67; 985-994.
22. Niu N, Zhang J, Guo Y, Zhao Y, Korteweg C, Gu J. Expression and distribution of immunoglobulin G and its receptors in the human nervous system. Int. J. Biochem. Cell Biol. 2011; 43; 556-563.
23. Niu N, Zhang J, Sun Y et al. Expression and distribution of immunoglobulin g and its receptors in an immune privileged site: the eye. Cell. Mol. Life Sci. 2011; 68; 2481-2492.
24. Chen Z, Huang X, Ye J et al. Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. Cancer 2010; 116; 1953-1963.
25. Lee G, Cheung AP, Ge B et al. CA215 and GNRH receptor as targets for cancer therapy. Cancer Immunol. Immunother. 2012; 61; 1805-1817.
26. Jiang C, Huang T, Wang Y, Huang G, Wan X, Gu J. Immunoglobulin G expression in lung cancer and its effects on metastasis. PLoS ONE 2014; 9; e97359.
27. Lee G, Ge B. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomark. 2009; 5; 177-188.
28. Lee G. Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications. Cancer Biomark. 2009; 5; 137-142.
29. Travis W, Colby T, Corrin B et al. Histological typing of lung and pleural tumors. Berlin: Springer, 1999.
30. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc. Am. Thorac. Soc. 2011; 8; 381-385.
31. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual, 7th ed. New York: Springer, 2010; xiv, 648 pp.